1
|
Liao CC, Chou PL, Cheng CW, Chang YS, Chi WM, Tsai KL, Chen WJ, Kung TS, Tai CC, Lee KW, Chen YC, Lin CY. Corrigendum to "Comparative analysis of novel autoantibody isotypes against citrullinatedinter-alpha-trypsin inhibitor heavy chain 3 (ITIH3) 542-556 peptide in serum from Taiwanese females with rheumatoid arthritis, primary Sjögren's syndrome and secondary Sjögren's syndrome in rheumatoid arthritis" [J Proteomics 141: (2016) 1-11]. J Proteomics 2019; 194:227. [PMID: 30553786 DOI: 10.1016/j.jprot.2018.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- C C Liao
- Proteomics Research Center, National Yang-Ming University, Taipei 112, Taiwan
| | - P L Chou
- Division of Allergy-Immunology-Rheumatology, Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan 330, Taiwan; Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
| | - C W Cheng
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
| | - Y S Chang
- Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
| | - W M Chi
- Department of Laboratory Medicine, Taipei Medical University-Shuang-Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
| | - K L Tsai
- Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
| | - W J Chen
- Department of Biotechnology and Animal Science, National Ilan University, Ilan 26047, Taiwan
| | - T S Kung
- School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
| | - C C Tai
- Department of Laboratory Medicine, Taipei Medical University-Shuang-Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
| | - K W Lee
- School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
| | - Y C Chen
- PhD Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan
| | - C Y Lin
- School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; PhD Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.
| |
Collapse
|
2
|
Ocean AJ, O’Brien K, Lee J, Matthews N, Holloway S, Christos P, Kung TS, Kaubisch A, Chen H, Wadler S. Phase II trial of FOLFOX6, bevacizumab and cetuximab in patients with Colorectal Cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4075 Background: Bevacizumab (B) + FOLFOX is widely accepted as a standard first-line therapy for metastatic colorectal cancer (mCRC). Recent treatment strategies have included the use of targeted therapies combined with chemotherapy to improve efficacy and to reduce chemotherapy-related toxicities. This Phase II study assesses first-line mFOLFOX6 + B + cetuximab (C), a monoclonal antibody approved for use in irinotecan-refractory mCRC. Methods: All pts had ECOG PS = 1, normal bone marrow, hepatic and renal function. Pts received mFOLFOX6 + B (5mg/kg) biweekly and C weekly (initially at 400 mg/m2, then subsequent doses at 250 mg/m2). Tumor assessment by imaging was done every 8 weeks. Primary endpoints are response rate, progression free-survival (PFS), overall survival (OS), and safety. The regimen would be considered promising if there were = 32 responses, or if = 60% of pts were progression-free for at least 8 months. Results: 67 pts (37 males, 30 females) were enrolled from 12/04–11/06. Median age was 57. Toxicities included Grade 4: neutropenia (6%), thrombosis/embolism (5%). Grade 3: neutropenia (13%), rash (13%), fatigue (11%), diarrhea (11%), abdominal pain (6%), neuropathy (5%), infection with ≤ Grade 2 ANC (4.5%). There were 2 deaths, 1 due to neutropenia and diarrhea and 1 to pulmonary fibrosis. As of 12/06, 9 pts were too early to evaluate. Of the remaining 58 pts, there were 32 responses (55%; 95% CI: 42%, 68%), including 3 CRs and 29 PRs; Median PFS was 9.6 months (95% CI: 8.8, 13.9 months), 71% were progression-free for at least 8 months, and median OS was not reached after a median follow-up of 11.4 months (range 1.5–25.2 months). Conclusions: Treatment with mFOLFOX6+ B + C met the pre-specified criteria for objective response and PFS to be considered promising. This regimen is associated with an acceptable toxicity profile and merits further evaluation. Supported by N01-CA-62204. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. J. Ocean
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - K. O’Brien
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - J. Lee
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - N. Matthews
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - S. Holloway
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - P. Christos
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - T. S. Kung
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - A. Kaubisch
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - H. Chen
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| | - S. Wadler
- NY Presbyterian Hosp, New York, NY; Montefiore Medical Center, Bronx, NY; National Cancer Institute, NIH, Bethesda, MD
| |
Collapse
|